Genzyme pursues innovation in discovery and development and the strategic acquisition of new resources. Our ability to execute creates the opportunities to support long-term growth.

In 2004, Genzyme established a commercial oncology franchise that provides a foundation for a portfolio of innovative products and services addressing the full spectrum of cancer care. We acquired ILEX Oncology, Inc., and as a result now have two marketed cancer therapies, a product candidate in phase 2 development, and a highly regarded clinical development team. We also expanded our oncology testing business through the acquisition of IMPATH's Physician Services business. Both of these additions complement our existing research and development programs in cancer. Our entrance into oncology with marketed products exemplifies our commitment to risk reduction through diversification.